CORC

浏览/检索结果: 共6条,第1-6条 帮助

限定条件    
已选(0)清除 条数/页:   排序方式:
DEVELOPMENT OF AN MF PATIENT REPORTED OUTCOME (PRO) TOOL FOR FDA QUALIFICATION: COMPREHENSIVE LITERATURE SEARCH AND PHYSICIAN COGNITIVE DEBRIEFING RESULTS 期刊论文
2016, 卷号: 101, 页码: 564-564
作者:  Geyer, H.;  Kosiorek, H.;  Dueck, A.;  Slot, S.;  Zweegman, S.
收藏  |  浏览/下载:9/0  |  提交时间:2020/01/04
SYMPTOMS, RISK CLASSIFICATION, AND SPLEEN SIZE IN JAK2 INHIBITOR-NAIVE MYELOFIBROSIS: IMPLICATIONS FOR JAK2 INHIBITOR TREATMENT 期刊论文
2016, 卷号: 101, 页码: 557-558
作者:  Scherber, R.;  Dueck, A.;  Geyer, H.;  Kosiorek, H.;  Kiladjian, J. J.
收藏  |  浏览/下载:4/0  |  提交时间:2020/01/04
IMPACT OF SPLENOMEGALY ON MPN SYMPTOMS AND ASSOCIATION WITH CLINICAL FEATURES: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP 期刊论文
2016, 卷号: 101, 页码: 555-555
作者:  Geyer, H.;  Scherber, R.;  Kosiorek, H.;  Dueck, A.;  Kiladjian, J. J.
收藏  |  浏览/下载:7/0  |  提交时间:2020/01/04
PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG) 期刊论文
2015, 卷号: 100, 页码: 261-262
作者:  Geyer, H.;  Kosiorek, H.;  Scherber, R.;  Dueck, A.;  Jean-Jacques, K.
收藏  |  浏览/下载:9/0  |  提交时间:2020/01/13
GENDER DIFFERENCES AND MPN SYMPTOM BURDEN: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG) 期刊论文
2014, 卷号: 99, 页码: 396-397
作者:  Geyer, H.;  Emanuel, R.;  Dueck, A.;  Kiladjian, J. J.;  Xiao, Z.
收藏  |  浏览/下载:2/0  |  提交时间:2020/01/13
DO MYELOPROLIFERATIVE NEOPLASMS (MPNS) HAVE STAGES? ANALYSIS OF RELATIONSHIP OF DISEASE DURATION, PROGNOSTIC SCORES, AND SYMPTOMATIC BURDEN OF 1467 MPN PATIENTS 期刊论文
2013, 卷号: 98, 页码: 114-115
作者:  Geyer, H.;  Emanuel, R.;  Dueck, A.;  Kiladjian, J.;  Slot, S.
收藏  |  浏览/下载:4/0  |  提交时间:2020/01/13


©版权所有 ©2017 CSpace - Powered by CSpace